Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

M. Lopez-Sublet; H. Bihan; G. Reach; Sophie Dupont; A. Didelot; J.-J. Mourad; A. Krivitzky; R. Dhote

doi:10.1016/j.diabet.2012.02.005

Journal articles

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

M. Lopez-Sublet H. Bihan G. Reach Sophie Dupont ¹ A. Didelot J.-J. Mourad A. Krivitzky R. Dhote

1 NEMESIS-CRICM - Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière

CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière

Abstract : Glutamic acid decarboxylase antibodies (GAD-abs) are an immunological factor involved in type 1 diabetes and other diseases involving the central nervous system. This report is of a patient with type 1 diabetes and a rare case of non-paraneoplastic limbic encephalitis mediated by anti-GAD65 antibodies that improved with the use of immunosuppressive drugs.

Document type :

Journal articles

Domain :

Computer Science [cs] / Medical Imaging

Complete list of metadata

https://hal.inria.fr/hal-00793692
Contributor : Olivier Colliot <>
Submitted on : Friday, February 22, 2013 - 5:58:12 PM
Last modification on : Thursday, March 21, 2019 - 12:26:50 PM

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

Identifiers

Collections

Citation

Export

Metrics

160

Contact Legal Notice Personal Data

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

Identifiers

Collections

Citation

Export

Share

Metrics

160

Contact Legal Notice Personal Data